Dexcom delivered a robust performance in Q4 2025, with worldwide revenue increasing by 13% year-over-year to $1.260 billion. The company also saw a substantial rise in GAAP operating income, up 860 basis points from the prior year, and launched its Dexcom G7 15 Day CGM system in the United States.

Dexcom delivered robust financial performance in Q3 2025, with worldwide revenue increasing by 22% year-over-year to $1.209 billion. The company also saw a substantial rise in GAAP operating income by 480 basis points and non-GAAP operating income by 130 basis points compared to the prior year.

DexCom delivered strong financial results in the second quarter of 2025, with revenue growing 15% year-over-year to $1.157 billion. The company saw an increase in GAAP operating income and reported solid GAAP and non-GAAP net income and EPS. DexCom also raised its fiscal year 2025 revenue guidance and announced a CEO succession plan.

Dexcom reported strong Q1 2025 performance with over $1 billion in revenue and maintained profitability, while securing broader PBM coverage and FDA clearance for its new 15-day CGM system.

DexCom achieved 8.00% YoY revenue growth in Q4 2024, reaching $1,113,500,000. However, net income declined significantly by 40.80% YoY due to increased operating expenses and margin pressure.

Dexcom's Q3 2024 revenue grew by 2% year-over-year to $994.2 million. The company launched Stelo, a new biosensor for adults with prediabetes and type 2 diabetes, and advanced its international product portfolio with Dexcom G7 and Dexcom ONE+ launches. The company is reiterating its fiscal year 2024 revenue guidance of approximately $4.00 - 4.05 billion.

DexCom reported a 15% year-over-year revenue increase to $1.004 billion for Q2 2024. The company launched Direct-to-Watch, secured coverage for Dexcom ONE in France, and advanced pump connectivity. However, execution did not meet expectations, prompting updated fiscal year 2024 guidance and a $750 million share repurchase program.

Dexcom reported a strong start to 2024 with revenue growth of 24% year-over-year to $921.0 million. The company also received FDA clearance for Stelo and launched Dexcom ONE+ in eight European countries.

Dexcom reported a strong fourth quarter in 2023, with revenue increasing by 27% year-over-year to $1.03 billion. GAAP operating income increased significantly, and net income saw a substantial rise. The company also provided annual guidance for 2024.

Dexcom's Q3 2023 revenue grew by 27% year-over-year to $975.0 million. The company raised its full-year revenue and margin guidance and announced a $500 million share repurchase program.

DexCom reported strong second-quarter results with a 25% increase in revenue to $871.3 million. The company also raised its full-year 2023 revenue and margin guidance, reflecting confidence in its growth trajectory and market opportunity.

Dexcom's first quarter 2023 results showed strong revenue growth of 18% year-over-year, driven by volume growth and new customer additions. The company launched Dexcom G7 in the United States and finalized coverage with the US Centers for Medicare & Medicaid Services. The company raised its 2023 revenue guidance.

Dexcom's Q4 2022 revenue grew by 17% to $815.2 million compared to the same quarter of the prior year. GAAP operating income was $125.4 million, or 15.4% of revenue, and GAAP net income was $91.8 million, or $0.22 per diluted share.

Dexcom's third-quarter revenue grew by 18% year-over-year to $769.6 million. The company launched G7 in five countries and expanded access to real-time CGM.

Dexcom reported a 17% increase in revenue to $696.2 million for Q2 2022, driven by volume growth and new customer additions. U.S. revenue grew by 11%, while international revenue increased by 39%. GAAP operating income was $77.0 million, and GAAP net income was $50.9 million, or $0.12 per diluted share.

DexCom, Inc. reported a 25% increase in worldwide revenue, reaching $628.8 million, driven by volume growth and new customer additions. The company secured CE Mark for the Dexcom G7 CGM System and advanced access to Dexcom CGM for people with diabetes.

DexCom reported a 23% increase in worldwide revenue for Q4 2021, reaching $698.2 million. However, GAAP operating income decreased significantly, and the company experienced a GAAP net loss of $19.4 million, or $0.20 per diluted share.

Dexcom reported a strong third quarter with revenue growth of 30% year-over-year to $650.2 million. The company's GAAP operating income was $118.3 million, or 18.2% of revenue. Dexcom also raised its full-year revenue and margin guidance.

Dexcom reported strong second quarter financial results with revenue growth of 32% compared to the same quarter of the prior year, reaching $595.1 million. The company increased its guidance for fiscal year 2021 revenue, Non-GAAP gross profit margin, Non-GAAP operating margin.

Dexcom reported a strong start to 2021 with a 25% increase in revenue compared to the same quarter last year, reaching $505.0 million. The company saw growth in both U.S. and international markets and raised its full-year revenue guidance based on these results.

Dexcom reported a strong Q4 2020 with a 23% increase in revenue to $568.9 million compared to the same quarter of the prior year. GAAP operating income was $104.0 million, representing 18.3% of revenue.

Dexcom's Q3 2020 results showed significant growth in revenue and operating income compared to the same quarter of the previous year. Revenue increased by 26% to $500.9 million, and GAAP operating income rose to $94.1 million, or 18.8% of revenue. The company also raised its full-year 2020 guidance.

DexCom reported a strong second quarter with revenue growth of 34% compared to the same quarter of the prior year, reaching $451.8 million. GAAP operating income was $67.8 million, representing 15.0% of revenue, and GAAP net income was $46.3 million, or $0.48 per diluted share. The company reinstated its 2020 revenue guidance to approximately $1.850 billion.

DexCom's first quarter 2020 results showed significant revenue growth driven by increased awareness and customer satisfaction with their G6 CGM technology. The company's response to the COVID-19 pandemic included making CGM systems available for hospital use and initiating a patient assistance program. Dexcom is temporarily suspending its 2020 guidance due to uncertainties related to the COVID-19 pandemic.

DexCom reported a strong fourth quarter and fiscal year 2019, with revenue growth of 37% in Q4 and 43% for the full year. The company achieved GAAP profitability for the first time and is well-positioned for long-term growth.